Literature DB >> 15643239

Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed?

Alexander Greenstein1, Nicola J Mabjeesh, Mario Sofer, Issac Kaver, Haim Matzkin, Juza Chen.   

Abstract

PURPOSE: We evaluated the efficacy of testosterone gel (T-gel) alone and in combination with sildenafil in hypogonadal patients with erectile dysfunction (ED).
MATERIALS AND METHODS: A total of 49 hypogonadal men (mean age 60.7 years) with ED participated for a mean of 20.2 months. Blood was tested for total and bioavailable testosterone, and prostate specific antigen. Sexual function was assessed using the International Index of Erectile Function questionnaire and a global assessment question (GAQ). Men received 1% 5 gm T-gel for 6 months, and 100 mg sildenafil was added to those with a "no" response to the GAQ after 3 months on testosterone supplement.
RESULTS: A total of 31 patients reported significant improvement in the sexual desire domain (from a mean +/- SD of 4.2 +/- 0.8 to 8.6 +/- 0.4) and erectile function (EF) domain (from 13.6 +/- 1.9 to 27 +/- 0.8) following treatment with testosterone supplement alone. One patient was excluded from study after urinary retention developed and 9 reported irritation at the gel application site. In spite of normalization of total and bioavailable testosterone values, and significant improvement of sexual desire domain scores, the EF of 17 men remained less than 26 or they responded "no" to the GAQ. These men received combined T-gel and sildenafil, after which all graded EF greater than 26 and responded positively to the GAQ.
CONCLUSIONS: Combined treatment with sildenafil and T-gel has a beneficial effect on ED in hypogonadal patients in whom treatment with testosterone supplement alone failed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15643239     DOI: 10.1097/01.ju.0000149870.36577.05

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  19 in total

Review 1.  Androgens are fundamental in the maintenance of male sexual health.

Authors:  Alvaro Morales
Journal:  Curr Urol Rep       Date:  2011-12       Impact factor: 3.092

Review 2.  Combination therapy for erectile dysfunction: an update review.

Authors:  Rohit R Dhir; Hao-Cheng Lin; Steven E Canfield; Run Wang
Journal:  Asian J Androl       Date:  2011-03-21       Impact factor: 3.285

Review 3.  Androgens and male aging: Current evidence of safety and efficacy.

Authors:  Louis J Gooren
Journal:  Asian J Androl       Date:  2010-02-15       Impact factor: 3.285

4.  The inter-relational effect of metabolic syndrome and sexual dysfunction on hypogonadism in type II diabetic men.

Authors:  N Amidu; W K B A Owiredu; C K Gyasi-Sarpong; H Alidu; B B Antuamwine; C Sarpong
Journal:  Int J Impot Res       Date:  2017-03-09       Impact factor: 2.896

Review 5.  The role of testosterone in erectile dysfunction.

Authors:  Giovanni Corona; Mario Maggi
Journal:  Nat Rev Urol       Date:  2009-12-08       Impact factor: 14.432

6.  Synergetic effect of testosterone and phophodiesterase-5 inhibitors in hypogonadal men with erectile dysfunction: A systematic review.

Authors:  Naif Alhathal; Ahmed M Elshal; Serge Carrier
Journal:  Can Urol Assoc J       Date:  2012-08       Impact factor: 1.862

7.  Total testosterone levels and the effect of sildenafil on type 2 diabetics with erectile dysfunction.

Authors:  Nabeel Najib Fadhil Hadeed; Imad Abdul-Jabar Thanoon; Samir Burhanaldin Al-Mukhtar
Journal:  Oman Med J       Date:  2014-01

8.  The benefits and risks of testosterone replacement therapy: a review.

Authors:  Nazem Bassil; Saad Alkaade; John E Morley
Journal:  Ther Clin Risk Manag       Date:  2009-06-22       Impact factor: 2.423

9.  Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations.

Authors:  C Wang; E Nieschlag; R Swerdloff; H M Behre; W J Hellstrom; L J Gooren; J M Kaufman; J-J Legros; B Lunenfeld; A Morales; J E Morley; C Schulman; I M Thompson; W Weidner; F C W Wu
Journal:  Eur J Endocrinol       Date:  2008-11       Impact factor: 6.664

Review 10.  Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction.

Authors:  R Sadovsky; G B Brock; S W Gutkin; S Sorsaburu
Journal:  Int J Clin Pract       Date:  2009-08       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.